Castle Biosciences (CSTL) revenue and earnings history
Castle Biosciences reported revenue of $344M for fiscal 2025 (year ended Dec 31, 2025), +3.7% on the year before, and net income of −$24.2M.
Over 7 years, from fiscal 2018 to fiscal 2025, revenue grew at a compound rate of +47.4% a year.
Revenue and net income, 8 fiscal years
Annual figures, newest first
| Fiscal year | Revenue | Operating income | Net income | Operating cash flow | Capital expenditure | Free cash flow | Stock-based pay | Share buybacks | Dividends paid | Cash at year end | Total debt at year end | Report |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025ended Dec 31, 2025 | $344M+3.7% | −$42.8M | −$24.2M | $64.3M | $36M | $28.3M | $45.9M | — | — | $117M | $10.1M | 10-K |
| 2024ended Dec 31, 2024 |
The latest quarter, insider trades and fund moves: Castle Biosciences (CSTL) on OQRO.
Common questions
What was Castle Biosciences's revenue in fiscal 2025?
$344M for the year ended Dec 31, 2025, as reported in its 10-K filed Feb 26, 2026. That is +3.7% on fiscal 2024 ($332M).
How fast has Castle Biosciences's revenue grown?
From $22.8M in fiscal 2018 to $344M in fiscal 2025: a compound annual growth rate of +47.4% over 7 years. This is arithmetic on the filed figures and says nothing about the years ahead.
Has Castle Biosciences been profitable?
Where these figures come from
The SEC’s companyfacts data: every figure Castle Biosciences tagged in XBRL in its annual and quarterly reports since 2009 (some reports carry a few earlier years as comparatives). For each fiscal year OQRO keeps the twelve-month totals from the annual report and the cash and debt at year end, and when a later report restates a year, the later figure. Read again whenever the company files.
Figures are as reported, in US dollars, with no adjustment for acquisitions, disposals or one-off items. Earnings per share are left out because a stock split changes them between reports. This page describes the past and is not investment advice. No language model wrote it.
